Compare AbbVie Inc (ABBV) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Prudential Financial Inc — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Prudential Financial Inc trades at $122.19 (market cap $42.13B). The key difference: AbbVie Inc is far larger — about 10.4× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ABBV | PRU | |
|---|---|---|
Market Cap | $438.19B | $42.13B |
Sector | Health | Financials |
52-Week High | $263.58 | $123.93 |
52-Week Low | $197.38 | $92.00 |
Enterprise Value | $502.45B | $70.91B |
Dividend Yield | 2.79% | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Prudential Financial (PRU) trades at $121.28, down 0.18% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 11 and net income margin of 6.04%, supported by Q2 2026 earnings beating estimates. Recent news highlights strategic refocusing and institutional buying interest, though China tax concerns caused temporary volatility.
Outlook remains positive due to earnings beats and capital-light strategy, but risks include interest rate sensitivity and geopolitical exposure. Analyst consensus is cautious with a $110 price target below current levels, suggesting limited upside despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
